Orphazyme A/S (ORPHA.CO)

DKK 1120.0

(-2.61%)

EBITDA Summary of Orphazyme A/S

Orphazyme A/S's latest annual EBITDA in 2023 was -26.04 Million DKK , up 99.97% from previous year.
Orphazyme A/S's latest quarterly EBITDA in 2024 Q2 was -1.49 Million DKK , up 1848100.0% from previous quarter.
Orphazyme A/S reported an annual EBITDA of -40.45 Million DKK in 2022, up 93.42% from previous year.
Orphazyme A/S reported an annual EBITDA of -603.91 Million DKK in 2021, down -1.97% from previous year.
Orphazyme A/S reported a quarterly EBITDA of -1.49 Million DKK for 2024 Q2, up 1848100.0% from previous quarter.
Orphazyme A/S reported a quarterly EBITDA of -14.2 Million DKK for 2023 Q4, down -8332651.32% from previous quarter.

Annual EBITDA Chart of Orphazyme A/S (2023 - 2015)

Historical Annual EBITDA of Orphazyme A/S (2023 - 2015)

Year	EBITDA	EBITDA Growth
2023	-26.04 Million DKK	99.97%
2022	-40.45 Million DKK	93.42%
2021	-603.91 Million DKK	-1.97%
2020	-615.69 Million DKK	-81.81%
2019	-334.31 Million DKK	-44.13%
2018	-230.28 Million DKK	-76.52%
2017	-130.27 Million DKK	-107.61%
2016	-62.94 Million DKK	-19.62%
2015	-58.47 Million DKK	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	-100.00 DKK	100.0%
2024 Q2	-1.49 Million DKK	1848100.0%
2023 Q4	-14.2 Million DKK	-8332651.32%
2023 Q3	170.50 DKK	100.0%
2023 Q1	25.00 DKK	100.0%
2023 Q2	-12.83 Million DKK	-51336100.0%
2023 FY	- DKK	33.16%
2022 Q1	-10.34 Thousand DKK	99.99%
2022 Q4	-12.12 Million DKK	0.0%
2022 FY	- DKK	93.42%
2022 Q2	-27.29 Million DKK	-263763.31%
2021 Q1	-20.26 Thousand DKK	99.99%
2021 FY	- DKK	-1.97%
2021 Q3	-86.4 Thousand DKK	99.98%
2021 Q4	-177 Million DKK	-204745.53%
2021 Q2	-391.58 Million DKK	-1932131.32%
2020 Q1	-121.65 Thousand DKK	99.93%
2020 FY	- DKK	-81.81%
2020 Q4	-360.03 Million DKK	-199067.99%
2020 Q3	-180.76 Thousand DKK	99.93%
2020 Q2	-243.3 Million DKK	-199900.82%
2019 Q1	-81.49 Thousand DKK	-34.12%
2019 Q3	-84.81 Thousand DKK	99.95%
2019 Q2	-162.98 Million DKK	-199900.0%
2019 Q4	-169.16 Million DKK	-199350.96%
2019 FY	- DKK	-44.13%
2018 Q3	-60.76 Thousand DKK	-11.74%
2018 Q4	-60.76 Thousand DKK	0.0%
2018 Q2	-54.37 Thousand DKK	0.0%
2018 FY	- DKK	-76.52%
2018 Q1	-54.37 Thousand DKK	-43.58%
2017 Q2	-27.27 Thousand DKK	0.0%
2017 Q3	-37.87 Thousand DKK	-38.85%
2017 Q4	-37.87 Thousand DKK	0.0%
2017 FY	- DKK	-107.61%
2017 Q1	-27.27 Thousand DKK	-67.01%
2016 Q4	-16.33 Thousand DKK	0.0%
2016 FY	- DKK	-19.62%
2016 Q2	-15.14 Thousand DKK	0.0%
2016 Q1	-15.14 Thousand DKK	0.0%
2016 Q3	-16.33 Thousand DKK	-7.86%
2015 FY	- DKK	0.0%

Peer EBITDA Comparison of Orphazyme A/S

Name	EBITDA	EBITDA Difference
ALK-Abelló A/S	913 Million DKK	102.853%
Bavarian Nordic A/S	2.05 Billion DKK	101.27%
Genmab A/S	5.56 Billion DKK	100.468%
Gubra A/S	-28.89 Million DKK	9.853%
Novo Nordisk A/S	113.33 Billion DKK	100.023%
Pharma Equity Group A/S	-24.79 Million DKK	-5.036%
Zealand Pharma A/S	-651.58 Million DKK	96.002%